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Background
Ipilimumab (IPI) in combination with fotemustine (FTM)
has shown a promising clinical activity in metastatic mela-
noma (MM) patients (pts) enrolled in the NIBIT-M1 trial
(Di Giacomo, et al., Lancet Oncology, 2012). This study
investigated changes in immunological parameters in the
course of treatment.
Material and methods
MM pts received an induction therapy with IPI 10 mg/kg
every 3 weeks (Q3W) for four doses and FTM 100 mg/m2
weekly for 3 weeks. Peripheral blood lymphocytes (PBMC)
and sera were collected at baseline, wk12, and wk24 to
perform phenotypic and functional T cell assays, and to
investigate humoral responses against a panel of tumor-
associated antigens (TAAs) and soluble NKG2D ligands
(sNKG2DL).
Results
Circulating central memory T (Tcm) cell populations,
both CD4+ and CD8+, co-expressing CD45RO, CD27,
CD28, CCR7, CD62L, were increased following treat-
ment both at wk12 and wk24. Interestingly, T cells co-
expressing CD4, BTLA and CD45RO were increased in
pts with clinical benefit, while CD8+ Tcm co-expressing
BTLA were augmented in pts with objective responses.
Circulating T cells reactive against NY-ESO-1, MART-1,
gp100 and TYRP-1, were found in 12/23 pts expressing
at least one of the HLA-A1, A2, -A3 or A24 alleles with
induction or augmentation of TAA reactivity in the
course of treatment. Moreover, at least one sNKG2DL
was found, though heterogeneously, in sera of 26/38 pts.
Of note, in 10 pts, down-modulation of at least 2/4 investi-
gated sNKG2DLs were detectable in relation with TAA-
specific responses. Finally, at baseline, antibodies against
NY-ESO-1, MAGE-A3, SSX-2, HMW-MAA, TYRP-1 and
MSLN were found in sera of 9-15-8-7-7-6 of 40 investi-
gated MM pts, respectively. Substantial changes were seen
during therapy showing induced humoral responses against
at least one investigated TAA in 10/40 pts at wk12 and/or
wk24. In addition, up-regulation, equivalent to at least two-
fold of the pre-existing antibody levels, against at least one
TAA was detected in 5/40 pts at wk12 and/or wk24.
Conclusions
Our results, although preliminary, indicate that IPI in com-
bination with FTM in MM pts induced changes in circulat-
ing T subpopulations and in their TAA-specific responses
as well as in circulating antibodies to selected TAAs
probably contributing to the observed clinical activity.
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